Bevacizumab Plus Chemotherapy versus Chemotherapy Alone As First-Line Treatment for Patients with RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Single Center Randomized Control Trial

2019 ◽  
Author(s):  
Wentao Tang ◽  
Li Ren ◽  
Qinghai Ye ◽  
Ye Wei ◽  
Guodong He ◽  
...  
Keyword(s):  
Randomized Control Trial ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Randomized Control ◽  
First Line Treatment

scholarly journals PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06811
Author(s):  
C. Restrepo-Aristizábal ◽  
L.M. Giraldo ◽  
Y.M. Giraldo ◽  
A.M. Pino-Pérez ◽  
F. Álvarez-Gómez ◽  
...  
Keyword(s):  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
First Line Treatment

Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience

2013 ◽  
Vol 30 (1) ◽  
Author(s):  
Lorenzo Livi ◽  
Pierluigi Bonomo ◽  
Icro Meattini ◽  
Gabriele Simontacchi ◽  
Daniela Greto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Single Center ◽  
First Line ◽  
Single Center Experience ◽  
First Line Treatment

Cetuximab maintenance therapy in unresectable metastatic colorectal cancer patients with wild-type RAS and BRAF: A single-center retrospective study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15004-e15004
Author(s):  
Tao Jiang ◽  
Xiaoyan Lin ◽  
Hao Chen ◽  
Jianwei Zhen ◽  
Bin Du ◽  
...  
Keyword(s):  
Maintenance Treatment ◽  
Observation Group ◽  
Line Treatment ◽  
Single Center ◽  
Wild Type ◽  
First Line ◽  
Free Survival ◽  
First Line Therapy ◽  
Line Therapy ◽  
First Line Treatment

e15004 Background: Cetuximab plus FOLFIRI (leucovorin, fluorouracil and irinotecan) is preferred first line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC) patients. However, the side effects often require dose-reductions or discontinuation calling for maintenance strategies to reduce toxicity and preserve efficacy. Therefore, we evaluated efficacy and safety of cetuximab maintenance therapy after first-line treatment in unresectable mCRC patients with RBWT. Methods: This single center, retrospective study enrolled patients (aged 18-71 years) with untreated mCRC with RBWT, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, with at least one measurable lesion according to response evaluation criteria in solid tumor (RECIST). All patients received first line cetuximab plus FOLFIRI every two weeks for 9-12 cycles, after which, patients with treatment response chose to either enter observation (stop treatment) or maintenance 1 (cetuximab plus irinotecan) group. After 6-12 cycles of maintenance 1, patients with treatment response entered maintenance 2 (cetuximab only). If patients progressed on maintenance 2, reintroduction of cetuximab plus FOLFIRI was suggested. Primary endpoint was failure-free survival (FFS); while secondary endpoints included disease control rate (DCR), objective remission rate (ORR) and progression free survival (PFS). Safety events were also evaluated. Results: Among 62 enrolled patients, 56 patients completed first-line treatment (DCR: 90.3%, ORR: 62.9%) and 30 patients entered maintenance 1 [median PFS1 (mPFS) =6.1 months, 95%CI: 6.0-6.2, DCR=60%, ORR=30%]. Of these, 18 entered maintenance 2 [mPFS2=6.6 months, 95%CI: 5.1-8.1, DCR=27.8%, ORR=5.6%]. The mFFS was significantly longer in maintenance 1 (12.8 months, 95%CI: 10.8-14.8) compared to observation group (3.0 months; hazard ratio [HR]: 0.21, 95%CI: 2.6-3.4, P<0.001). Overall mFFS was 19.0 (95%CI: 11.0-27.0) in maintenance and 9.5 months in observation group (HR: 0.195, 95%CI: 7.4-11.6; P<0.001). Rash acneiform, mucositis and asthenia were the common adverse events observed during maintenance treatment. Conclusions: Maintenance treatment with cetuximab after first line therapy significantly improved FFS, with acceptable safety profile in untreated mCRC RBWT patients.

Sign in / Sign up

Export Citation Format

Share Document